Real-World Utilization and Outcomes with Dacomitinib First-Line Treatment for EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer among Asian Patients – A Multi-Center Chart Review (ARIA)
Advanced Non Small Cell Lung Cancer with EGFR mutation on Dacomitinib as First Line Treatment for Asian Patients (Observational)
University of Malaya Medical Centre (UMMC)
PRINCIPAL INVESTIGATOR
Dr Ho Gwo Fuang
fuang@ummc.edu.my
CONTACT
SC: Wei Ying 03-79492120 (Research Room)
Pantai Hospital Kuala Lumpur
PRINCIPAL INVESTIGATOR
DR JOHN LOW SENG HOOI
john.low@pantaidr.my
CONTACT
General Line: 03 – 2296 0888
CRC: 03 – 2280 1320 / 2280 1321 / 2280 1322
Beacon Hospital Sdn Bhd
PRINCIPAL INVESTIGATOR
DR THO LYE MUN
drtho.oncology@gmail.com
CONTACT
General line: 03 7620 7979 / 03 7787 2992
CRC: 03 -7787 2854 (Tel)
clinicalresearch@beaconhospital.com.my (Email)
Plasma Molecular Profiling in ALK inhibitor resistant non-small cell lung cancer (ARTOG-004)
Non Small Cell Lung Cancer with ALK Inhibitor Resistant in Asian (Liquid Biopsy)
Pantai Hospital Kuala Lumpur
PRINCIPAL INVESTIGATOR
DR THO LYE MUN
drtho.oncology@gmail.com
CONTACT
General Line: 03 – 2296 0888
CRC: 03 – 2781 0888 Ext 4519/4520/4522
University of Malaya Medical Centre (UMMC)
PRINCIPAL INVESTIGATOR
Dr Ho Gwo Fuang
fuang@ummc.edu.my
CONTACT
SC: Yok Yong 03-79492120 (Research Room)
A prospective, molecular profiling study of mutational genes in Asian patients with Non-Small Cell Lung Cancer. (Non-interventional study)(ATORG001)
Non Small Cell Lung Cancer in Asian (Observational)
Pantai Hospital Kuala Lumpur
PRINCIPAL INVESTIGATOR
DR THO LYE MUN
drtho.oncology@gmail.com
CONTACT
General Line: 03 – 2296 0888
CRC: 03 – 2781 0888 Ext 4519/4520/4522
University of Malaya Medical Centre (UMMC)
PRINCIPAL INVESTIGATOR
Dr Ho Gwo Fuang
fuang@ummc.edu.my
CONTACT
SC: Wei Ying 03-79492120 (Research Room)
Beacon Hospital Sdn Bhd
PRINCIPAL INVESTIGATOR
Dr Azura Rozila Ahmad
CONTACT
General line: 03 7620 7979 / 03 7787 2992
CRC: 03 -7787 2854 (Tel)
clinicalresearch@beaconhospital.com.my (Email)
A Prospective, Multicentre, Genomic Profiling Study In Patients With Locally Advanced Or Metastatic Non-small Cell Lung Cancer (NSCLC) In Malaysia Using Foundation Medicine (ML41262)
Malaysia, Non Small Cell Lung Cancer, Advnced or Metastatic
Beacon Hospital Sdn Bhd
PRINCIPAL INVESTIGATOR
DR THO LYE MUN
drtho.oncology@gmail.com
CONTACT
General line: 03 7620 7979 / 03 7787 2992
CRC: 03 -7787 2854 (Tel)
clinicalresearch@beaconhospital.com.my (Email)
Plasma Molecular Profiling in ALK Inhibitor Resistant Non-Small Cell Lung Cancer
Progressed 1-2 ALK inhibitor with at least one second generatiion of ALK inhibitor
University of Malaya Medical Centre (UMMC)
Genomic Profiling Study In Subjects With Locally Advanced/Metastatic Non-Small Cell Lung Cancer (ROCHE)
Non-Small Cell Lung Cancer, Locally Advanced or Metastatic
Kuala Lumpur Hospital (HKL)
PRINCIPAL INVESTIGATOR
Dr Ros Suzanna Ahmad Bustamam
rossuzanna@gmail.com
CONTACT
General line: 03 – 2615 5555
CRC: 03 – 2615 5555 Ext. 6262 (Tel)
crc.hkl@moh.gov.my (email)
Crc Hkl / Clinical Research Centre HKL (Facebook)
A Prospective, Multicentre, Genomic Profiling Study In Patients With Locally Advanced Or Metastatic Non-small Cell Lung Cancer (NSCLC) In Malaysia Using Foundation Medicine (ML41262)
Malaysia, Non Small Cell Lung Cancer, Advnced or Metastatic
Beacon Hospital Sdn Bhd
PRINCIPAL INVESTIGATOR
DR THO LYE MUN
drtho.oncology@gmail.com
CONTACT
General line: 03 7620 7979 / 03 7787 2992
CRC: 03 -7787 2854 (Tel)
clinicalresearch@beaconhospital.com.my (Email)
A Study of Non-Small Cell Lung Cancer Genomic Screening to Encourage Precision Medicine in Asia Pacific (LC-SCRUM-AP)
Asia Pacific, Non Small Cell Lung Cancer, Advnced or Metastatic
Kuala Lumpur Hospital (HKL)
PRINCIPAL INVESTIGATOR
DR MUTHUKKUMARAN A/L THIAGARAJAN
drmuthuk@gmail.com
CONTACT
General line: 03 – 2615 5555
CRC: 03 – 2615 5555 Ext. 6262 (Tel)
crc.hkl@moh.gov.my (email)
Crc Hkl / Clinical Research Centre HKL (Facebook)
Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab With Pembrolizumab) in Combination With Concurrent Chemoradiotherapy Followed by MK-7684A Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Unresectable, Locally Advanced, Stage III NSCLC (MK-7684A-006/KEYVIBE-006)
Kuala Lumpur Hospital (HKL)
PRINCIPAL INVESTIGATOR
Sandya Subramaniam
CONTACT
Amirah Mohamed
Pulau Pinang Hospital
PRINCIPAL INVESTIGATOR
Tan Ai Lian
CONTACT
Nurain Sidiiqin